A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors

• Status: Active, not recruiting
• Trial end date: 2021-11-30
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the tolerability of the study drug LY3039478 in Japanese participants with advanced solid tumors.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company

Criteria

Inclusion Criteria:

• Histological or cytological evidence of a diagnosis of solid tumor that is advanced and/or metastatic.

• In the judgment of the investigator, participants must be appropriate candidates for experimental therapy after available standard therapies have failed or for whom standard therapy is not appropriate.

• Performance status of ≤1 on the Eastern Cooperative Oncology Group (ECOG) scale.

• Adequate organ function, including hematologic, hepatic, and renal.

• Estimated life expectancy of ≥12 weeks.

Exclusion Criteria:

• Received previous therapy for cancer within 14 or 21 days of the initial dose of study drug for a nonmyelosuppressive or myelosuppressive agents, respectively.

• Have serious preexisting medical conditions.

• Have current or recent (within 3 months of study drug administration) gastrointestinal disease with chronic or intermittent diarrhea.

• Have an active bacterial, fungal, and/or known viral infection.

• Have known acute or chronic leukemia or current hematologic malignancies that may affect the interpretation of results.